FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27, 2025
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.